Aurobindo Pharma gets nod for for fixed dose triple combination for HIV

Aurobindo Pharma has received approval from SAHPRA and tentative approval from USFDA for the Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (DLT) tablets to treat HIV patients.

New Delhi: Aurobindo Pharma Limited has recently announced that the company has received approval from the South African Health Products Regulatory Authority (SAHPRA) for its Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (DLT) tablets, 50mg/300mg/300mg, the first-line preferred regimen for HIV patients as per latest WHO guidelines.

Prior to SAHPRA's approval, Aurobindo has received tentative approval for the drug from US Food and
Drug Administration and launched in Sub-Saharan African markets as part of its commitment to bring
affordable HIV drugs to millions of patients globally. As of filing to BSE

Aurobindo is now among the first few companies which have received approval for this product. This
approval demonstrates our commitment towards HIV patients and enables the company to participate in South African HIV tender as well as launch in private market. The approval further strengthens
Aurobindo's HIV product basket in South Africa, which has the potential to improve the lives of millions
of patients.